HU-210
Template:Short description Template:Cs1 config Template:Drugbox HU-210 is a synthetic cannabinoid that was first synthesized in 1988 from (1R,5S)-myrtenol[1] by a group led by Raphael Mechoulam at the Hebrew University.[2][3][4] HU-210 is 100 to 800 times more potent than natural THC from cannabis and has an extended duration of action.[5] HU-210 has a binding affinity of 0.061 nM at CB1 receptors[6] compared to 40.7 nM for Δ9-THC.[7] The binding pose of HU-210 to the CB1 receptor is similar to other synthetic cannabinoids.[8]
Effects and research
HU-210, the (–) enantiomer, is an ultrapotent cannabinoid, while its (+) enantiomer HU-211 is not a cannabinoid, but an NMDA antagonist with neuroprotective effects.[9][10]
HU-210 has an oral LD50 of 5,000 mg/kg in rats and 14,200 mg/kg in rabbits,[11] and an LDLO (lowest lethal dose) of 143 mg/kg in humans.[11] This is more toxic than Δ8-THC; in monkeys and dogs, 9,000 mg/kg of Δ8-THC was nonlethal.[12][13]
Chemistry
HU-210 is the enantiomer of HU-211 (dexanabinol). The original synthesis of HU-210 is based on an acid-catalyzed condensation of (–)-Myrtenol and 1,1-Dimethylheptylresorcinol (3,5-Dihydroxy-1-(1,1-dimethylheptyl)benzol).[1]
Legal status
HU-210 is not listed in the schedules set out by the United Nations' Single Convention on Narcotic Drugs from 1961 nor their Convention on Psychotropic Substances from 1971,[14] so the signatory countries to these international drug control treaties are not required by said treaties to control HU-210.
New Zealand
HU-210 is banned in New Zealand as of 8 May 2014.[15]
United States
HU-210 is not explicitly listed in the list of scheduled controlled substances in the USA.[16] A brief profile of HU-210 written and published by the Drug Enforcement Administration (DEA) in 2009, but removed in later years, stated that HU-210 is a Schedule I controlled substance under the Controlled Substances Act due to being similar to THC.[17] A version of the document (updated in 2013), now in PDF form, exists on the DEA Office of Diversion Control's website.[18] In that PDF, the DEA reasserts that HU-210 is a Schedule I substance. The DEA currently considers HU-210 a Schedule I controlled substance under the umbrella of ‘tetrahydrocannabinols’ under CSCN 7370.[19]
Alabama
HU-210 is a Schedule I controlled substance in Alabama.[20] Template:Quote
Florida
HU-210 is a Schedule I controlled substance, categorized as a hallucinogen, making it illegal to buy, sell, or possess in the state of Florida without a license.[21] Template:Main other
Vermont
Effective January 1, 2016, HU-210 is a regulated drug in Vermont designated as a "Hallucinogenic Drug."[22]
See also
References
Further reading
- Script error: No such module "Citation/CS1".
- Script error: No such module "Citation/CS1".
Script error: No such module "Navbox". Script error: No such module "Navbox". Template:Cannabinoidergics
- ↑ a b Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "Citation/CS1".
- ↑ a b Script error: No such module "citation/CS1".
- ↑ Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ Script error: No such module "citation/CS1".